CN105963357A - Drug for treating atherosclerosis - Google Patents
Drug for treating atherosclerosis Download PDFInfo
- Publication number
- CN105963357A CN105963357A CN201610415112.2A CN201610415112A CN105963357A CN 105963357 A CN105963357 A CN 105963357A CN 201610415112 A CN201610415112 A CN 201610415112A CN 105963357 A CN105963357 A CN 105963357A
- Authority
- CN
- China
- Prior art keywords
- industrial hemp
- fructus cannabis
- medicine
- extract
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a drug for treating atherosclerosis. The drug for treating atherosclerosis is prepared by evenly mixing, by weight, 0.3-99.7 parts of industrial hemp seed extract and 0.3-99.7 parts of industrial cannabinoids. Experiments prove that the drug can obviously reduce blood fat, improve the content of serum NO, reduce the ET-1 content and restrain plaque progression, is better than cannabidiol in effect, has the definite effect of treating atherosclerosis and has a good market application prospect.
Description
Technical field
The invention belongs to treatment of atherosclerosis drug world, concretely relate to a kind of big with industry
The atherosclerotic pharmaceutical composition for the treatment of that fiber crops are prepared for primary raw material.
Background technology
The plantation of Fructus Cannabis is with a long history, ancient times Fructus Cannabis be mainly used in fabrication and processing rope, fishing net, clothing and
Paper making raw material, and oils and fats, food etc..Development and progress along with society, it has been found that contain in Fructus Cannabis
Having a kind of toxic component (tetrahydrocannabinol) that people can be made to cause unreal addiction, American-European many countries are once considerably long
Forbid cultivating in period Fructus Cannabis.Owing to the economic use value of Fructus Cannabis is high, to the eighties in 20th century, some
Low toxicity Hemp Varieties the plantation that puts it over have been cultivated in European countries' research.Nineteen ninety, the European Community took the lead in
Emergency fixes agricultural policy, has abolished the ban of Fructus Cannabis of forbidding cultivating, and starts to recover the production of Fructus Cannabis and research.
The state such as the U.S., Canada, Australia relieves the ban of Fructus Cannabis plantation, whole world Fructus Cannabis growing surface subsequently
Amassing to have had with fiber production and increase rapidly, the exploitation of industrial hemp are started by American-European countries again, state
The demand of ecological Fructus Cannabis is also being increased rapidly by market, border.According to the economic attribution of Fructus Cannabis, for making full use of
It services for the mankind, and within 1988, the United Nations's clear stipulaties does not possess extraction toxic component (tetrahydrocannabinol
THC) it is worth or sucks directly as drugs, specializing in the raw material Fructus Cannabis of industrial use, industrial hemp (its
Tetrahydrocannabinol content in trophophase Fructus Cannabis floral leaf is less than 0.3%), legal can carry out scale kind
Plant and utilize with industrialized developing.
Industrial hemp be show unique characteristics, living resources that comparative advantages are prominent.Industrial hemp and conventional toxic
Fructus Cannabis has essential distinction, and industrial hemp is the raw material of industry product of a class Non-toxic, has high warp
Ji value.Successively 25 industrial hemp kinds are selected altogether to countries in the world at the end of 2003,
And seven states such as the method for European Union, moral, English the most all become industrial hemp and mainly plant manufacturing country, big with industry
Flaxen fiber and fiber crops seed and flower thereof, leaf, root, stem are that raw material carries out series of products research and development and comprehensively opens with industrialization
Send out, process major product jute skin fiber, stalk core fibre, hemp seed oil fat and seed dregs of rice egg in industrial hemp primary
In vain, medicinal standard extract realize industrialization produce on the basis of, carry out deep processing and utilization further,
The product derived from has reached more than 25,000 kinds, contains the clothing of the mankind, food, shelter, row, use
Each big series products.The research of industrial hemp industry, develop and production be concentrated mainly on Europe, Canada,
The technology developed countries such as the U.S..The development of industrial hemp industry, first nontoxic from selection-breeding or low poison
Industrial hemp new varieties start, and achieve plantation and the hi-tech industrialization of scale based on this
Comprehensive development and utilization, define the quick increasing of " emerging pollution-free industry group " and infant industry economy
Long point.
Fructus Cannabis is Fructus Cannabis dry mature fruit, is generally used as medicine by Fructus Cannabis ancient times, and dietetic therapy is the most on the books.
Fructus Cannabis is included in " being medicine and food " " medicine-food two-purpose " list by health ministry.
The property of medicine of Fructus Cannabis and pharmacology be: sweet, flat.Return spleen, stomach, large intestine channel.Function cures mainly: moisturize, sliding
Intestinal, treating stranguria, invigorate blood circulation.Control dryness of the intestine constipation, quench one's thirst, pyretic stranguria, migratory arthralgia, dysentery.Menoxenia, scabies,
Tinea leprosy.Those benefits in detail is had to record in medical book, such as " herbal classic ": " invigorating the spleen and replenishing QI.”；Tang Materia Medica:
" main five kinds of over strain.”；" Handbook of Prescriptions for Emergencies ": " control extreme thirst, day eclipse number bucket, hot urination person: pockmarks one liter,
Three liters of water, boils three, four boilings, and extracting juice drinks it.”；" Japan hanako materia medica ": " qi-restoratives labor, long muscle,
Stimulating milk secretion, only quenches one's thirst, and expedites the emergence of.Control perverse and unreasonable manner to produce.”；Supplement to the Herbal: " therapeutic method to keep the adverse QI flowing downwards, diuresis go
Migratory arthralgia skin is stupid, fries and makes perfume (or spice) smash to pieces, urine leaching juice clothes；Married woman's footling presentation gulps down two or seven pieces.”；" dietetic therapy is originally
Grass ": " extracting juice is cooked congee, and goes the five internal organs wind, lung moistening.Control that joint is obstructed, deal with, promoting blood circulation.”.
The equal hyoscine of floral leaf of Fructus Cannabis.The property of medicine of Folium Cannabis and pharmacology be: pungent；Poisonous.Return lung；Bladder；
Large intestine channel.Function cures mainly: pain relieving, and Dingchuan drives ascarid.Cure mainly asthma, fall and flutter pain, ascariasis.Fiber crops
The property of medicine and the pharmacology of flower be: bitter；Pungent；Warm in nature；Poisonous.Function cures mainly: dispel the wind；Invigorate blood circulation；Hair growth promoting.
Main air disease numb limbs and tense tendons；Pruritus all over；Women's amenorrhea.
Atherosclerosis (Atherosclerosis, AS) is a kind of common serious harm human health
Cardiovascular and cerebrovascular disease.Epidemiological study, the patient that China is perplexed by atherosclerosis every year exceedes
70000000, and prevalence and sickness rate are in ascendant trend year by year, 40-49 year crowd in, inspection
Go out rate and be respectively 58.36% and 88.31%, it has also become one of primary killers that middle-aged and elderly people is dead.
Atherosclerosis is a kind of disease invading systemic arterial system, can have the asymptomatic of many decades
Phase, the cause of disease is complicated, the course of disease is very long, including endothelial injury, and low density lipoprotein, LDL (LDL) oxidative modification,
High-density lipoprotein concentration (HDL) increases, Adherence of Monocytes, smooth muscle cell increment and fibrous plaque
Formed.Under the effect of Other Risk Factors (hypertension, high cholesterol count, hyperlipemia etc.), dynamic
Arteries and veins endothelial injury necrosis peel off, produce and release cells adhesion factor and somatomedin so that platelet and
Mononuclear cell adheres in this place, and then mononuclear cell enters subcutaneous space and transfers macrophage to；Middle film smooths
Myocyte travels to propagation or apoptosis at inner membrance；Macrophage and smooth muscle cell picked-up cholesterol change into bubble
Foam cell, forms the early lesion i.e. fat stricture of vagina of AS.On this basis, progressively develop into by non-viable non-apoptotic cell
The fibre that the fibrous tissue of fragment, cholesterol and ester thereof, vascular smooth muscle, macrophage and densification is constituted
Dimension speckle.Speckle forms rear unstable factor and causes fibrous cap to rupture formation blood vessel blockage, stasis etc..Dynamic
Pulse atherosclerosis and hypertension, coronary heart disease, apoplexy have close ties, serious threat the health of the mankind,
Bring huge economy and living burden also to society and family.Therefore, strengthen atherosclerotic
Treatment is China or even whole world problem demanding prompt solution, extensively finds medicine and has the most far-reaching reason
Opinion and practical significance.
Cannabidiol (CBD) is that a kind of nontoxic of extraction from Fructus Cannabis floral leaf can be used for medicine, cosmetic
Product, the aldehydes matter of a kind of high added value of health food.At present, Israel, the U.S., Britain etc. are sent out
Reach country done raw material with it and developed multiple special effect medicine and cosmetics.CBD is non-in Fructus Cannabis
Additive composition, can hinder THC to affect nerve system of human body, and have spasmolytic, antirheumatic
The pharmacologically active such as arthritis, anxiety, also has the report in terms for the treatment of atherosclerosis, but individually
The therapeutic effect using cannabidiol (CBD) is unsatisfactory.Therefore developing new activity high, poison is secondary to be made
Seem the most necessary with little medicine.
Summary of the invention
Present invention aims to the deficiencies in the prior art, it is provided that a kind of with industrial hemp for the most former
The atherosclerotic pharmaceutical composition for the treatment of of material preparation.
The purpose of the present invention is achieved by the following technical programs.
Except as otherwise noted, percent of the present invention is mass percent.
One treats atherosclerotic medicine, it is characterised in that by the raw material blending of following weight parts
Make: industrial hemp Fructus Cannabis extract 0.3 part～99.7 parts, industrial hemp Urtica cannabina L. element 99.7 parts～
0.3 part.
The raw material composition of described treatment atherosclerosis medicine is preferably industrial hemp Fructus Cannabis and extracts
Thing 40 parts and industrial hemp Urtica cannabina L. element 60 parts.
Wherein, described industrial hemp Fructus Cannabis extract is prepared by the following method and forms:
(1) ripe industrial hemp Fructus Cannabis is taken, drying, remove impurity, standby after pulverizing；
(2) under the conditions of 20～85 DEG C, extracting pulverizing Fructus Cannabis material with ethanol, ethanol is dense
Degree is 95%～100% (V/V), and solid-liquid ratio is 1:5～1:20；
(3) leach lixiviating solution, after concentrating under reduced pressure, be industrial hemp Fructus Cannabis extract.
When industrial hemp Fructus Cannabis being extracted with ethanol, following various ways can be used to carry out: as
Extract under room temperature, every batch materials extraction 2 times, each 7～10 days；Under the conditions of 60～85 DEG C, add
Heat extraction 2 times, each 1～3 hour；Ultrasonic assistant extracts, ultrasonic frequency 30～60kHz,
Power 100～1000W, extraction time 30～60min, extraction temperature 25～50 DEG C；Also can adopt
By other prior aries such as microwave radiation exaraction.
Described industrial hemp Urtica cannabina L. element is prepared by the following method and forms:
(1) flower of industrial hemp, leaf, fiber crops bran or the mixture of three, drying, remove impurity, powder are taken
It is broken to 10～60 mesh；
(2) supercritical carbon dioxide extraction: the above-mentioned industrial hemp raw material crushed is put into supercritical
In carbon dioxide extraction apparatus, control extraction temperature 40～50 DEG C, extraction time 30～90min, extraction
Pressure power 25～35Mpa, carbon dioxide flow 40kg/h, extract is collected in separating still outlet；
(3) the extract ethanol elution of 95%～100% (V/V) of 0.2～10 times of volume,
Washing steps is 1～3 time；
(4) eluent is collected, concentrating under reduced pressure, vacuum drying, i.e. obtain industrial hemp Urtica cannabina L. element after pulverizing.
The flower of described industrial hemp, leaf, the optimum ratio of fiber crops bran three's mixture are 1:3:2.
Common Folium Cannabis, Flos Cannabis are respectively provided with toxicity (containing tetrahydrocannabinol THC marijuana hemp extremely
Unreal material).For getting rid of the toxicity of crude drug, present invention preferably employs the industrial hemp kind of Yunnan growth
Flower, leaf, fiber crops bran and the Fructus Cannabis of " cloud fiber crops No. 1 " are as raw material.By China's relevant legal documents
Regulation, " cloud fiber crops No. 1 " can only plant within the border in Yunnan, and its flower, leaf, numb bran can only be in Yunnan
Domestic processing.
The pharmaceutical composition of the present invention can make different pharmaceutical preparation further, including oral agents and pin
Agent, wherein oral agents includes capsule, oral liquid, tablet, drop pill, granule etc., and injection includes note
Penetrate liquor type and freeze-dried powder injection type etc..When preparing oral formulations, available auxiliary type agent is permissible
It it is the conventional filler such as starch, dextrin or cyclodextrin, sucrose, stearate.Lyophilized injectable powder can lead to
Prepared by the methods such as aseptic spray drying, low-temperature vacuum drying, lyophilization of crossing.Prepared by the later stage of each preparation
Processes and apparatus all belongs to the routine techniques of pharmaceutical field, and this is not construed as limiting by the present invention, therefore at this most in detail
State.
The pharmaceutical composition of the present invention can substantially reduce blood fat, improve serum NO levels, reduction ET-1
Content, and suppress plaque progression, effect to be better than cannabidiol, there is clear and definite treatment atherosclerosis
Effect.
Detailed description of the invention
Below by embodiment, the present invention is described in further detail, but embodiment is not to this
The restriction of bright technical scheme.
Embodiment 1
Use flower, leaf, fiber crops bran and the Urtica cannabina L. of the industrial hemp kind " cloud fiber crops No. 1 " of Yunnan growth
Core is as raw material.Take maturation industrial hemp Fructus Cannabis, drying, remove impurity, standby after pulverizing；Use second
Alcohol to pulverize Fructus Cannabis material extract (under the conditions of 60～85 DEG C, heating extraction 2 times, each 1～
3 hours), concentration of alcohol is 95%～100% (V/V), and solid-liquid ratio is 1:5～1:20；Leach
Lixiviating solution, is industrial hemp Fructus Cannabis extract after concentrating under reduced pressure.
Take the flower of industrial hemp, leaf, fiber crops bran 1:3:2 mass ratio mixture, drying, remove impurity,
It is crushed to 10～60 mesh；Supercritical carbon dioxide extraction: the above-mentioned industrial hemp raw material crushed is thrown
Enter in supercritical carbon dioxide extraction apparatus, control extraction temperature 40～50 DEG C, extraction time 30～
90min, extracting pressure 25～35Mpa, carbon dioxide flow 40kg/h, separating still outlet is collected
Extract；The extract ethanol elution of 95%～100% (V/V) of 0.2～10 times of volume,
Washing steps is 1～3 time；Collect eluent, concentrating under reduced pressure, vacuum drying, after pulverizing, obtain industry
Fructus Cannabis Urtica cannabina L. element.
Take industrial hemp Fructus Cannabis extract 40 parts, industrial hemp Urtica cannabina L. element 60 parts, mixing, obtain this
Invention medicine B.
Embodiment 2
Repeat embodiment 1, have following difference: when industrial hemp Fructus Cannabis being extracted with ethanol,
Extract under room temperature, every batch materials extraction 2 times, each 7～10 days.Take the flower of industrial hemp, leaf,
The mixture of fiber crops bran 1:1:1 mass ratio is as the extraction raw material of industrial hemp Urtica cannabina L. element.
Take industrial hemp Fructus Cannabis extract 0.3 part, industrial hemp Urtica cannabina L. element 99.7 parts, mixing, obtain
Medicine A of the present invention.
Embodiment 3
Repeat embodiment 1, have following difference: when industrial hemp Fructus Cannabis being extracted with ethanol,
Employing ultrasonic assistant extracts, ultrasonic frequency 30～60kHz, power 100～1000W, extracts
Time 30～60min, extraction temperature 25～50 DEG C.Take the flower of industrial hemp, leaf, fiber crops bran 3:2:1 matter
The mixture of amount ratio is as the extraction raw material of industrial hemp Urtica cannabina L. element.
Take industrial hemp Fructus Cannabis extract 99.7 parts, industrial hemp Urtica cannabina L. element 0.3 part, mixing, obtain
Medicine C of the present invention.
Embodiment 4
Example 1 gained medicine 100 grams (crosses 80 mesh sieves), adds 60 grams of microcrystalline Cellulose, mistake
80 mesh sieves three times, mix homogeneously, spray into 95% ethanol solution, soft material processed, cross 40 mesh sieves and pelletize,
60 DEG C of dry half an hour, it is sub-packed in 3# capsule, aluminium plastic composite packaging, prepares treatment Atherosclerosis
Change medicine capsule.
Embodiment 5
Example 2 gained medicine, admixture doses 5～the dried starch of 20% and 1～the tristearin of 5%
Acid magnesium etc., blended, pelletize, be dried, tabletting, prepare treatment atherosclerosis medicinal tablet.
Embodiment 6
The adjuvants such as Example 3 gained medicine, adds sucrose water and the preservative of convention amount, stabilizer.
Filtration, sterilizing, be distributed in 10mL bottle, makes treatment atherosclerosis medicine oral liquid.
Embodiment 7
Example 1 gained medicine, adds water for injection and dissolves, add 2.0 ‰ activated carbons, stir,
Filter, continue, with 0.45 μm, 0.22 μm microporous filter membrane classified filtering, to supplement water for injection, subpackage
In cillin bottle, lyophilization, recharge high-purity nitrogen, jump a queue, gland, packaging, prepare treatment dynamic
Pulse atherosclerosis medicaments injection.
Application Example 1 present invention impact on Rabbits of Atherosclerosis
Taking healthy new zealand rabbit, body weight 2.0-2.5kg, male and female half and half, pellet balance is fed 1 week
After, taking 10 at random and be only used as Normal group, feed with normal diet, remaining is high fat modeling group,
Give high lipid food to feed (by 1% cholesterol, 5% Adeps Sus domestica, 10% yolk powder, 84% normal diet ratio
Example makes), each group every rabbit total amount of taking food every day is equal, is limited to 150g, freely drinks water.After 12 weeks
High fat modeling group takes 2 experimental rabbits and puts to death, and light Microscopic observation aortic tunica intima substantially thickens, with greatly
Amount foam cell, endotheliocyte arrangement disorder, discontinuous, a large amount of smooth muscle cell migration inner membrances, it is considered as
Modeling success.
High fat modeling group rabbit is randomly divided into 5 groups, often group 10, i.e. Normal group, model group,
Cannabidiol group, A, B, C group of the present invention.In addition to Normal group still feeds normal diet, its
Remaining each group feeds above-mentioned high lipid food.Of the present invention group and cannabidiol group gavage respectively give 20mg/kg；
Remaining group gives respective amount normal saline.All animals freely drink water, and are administered once daily administration totally 8 weeks.
All animals are being administered after 8 weeks extraction ear vein blood 5mL on an empty stomach, for each group of rabbit anteserum TC of detection,
TG, LDL, HDL, NO, ET-1 use；Blood drawing puts to death all experiments with air tap inserting method after terminating
Animal, aseptic taking-up aortic root to aorta is worn artery segment at diaphram and, as specimen, is removed adventitia attached
Tissue, cut off along tremulous pulse major axis, take speckle the most notable position artery segment 1cm, be placed in 10% Fu Er
Malin's solution soaks the piece of tissue being trimmed to about 1cm × 0.15cm × 0.15cm after fixing, for disease
Reason histological observation.
Use enzymatic assays serum TC, TG, LDL, HDL level；NO measures and uses nitrate reductase
Enzyme process；ET-1 uses radio immunoassay.Measure plaque area: the sliced machine of pathological tissue block presses 4
The thickness cutting of μm, uses HE dyeing to make pathological section, calculates plaque area and account for whole piece aorta
The percentage ratio of area.
Pathological changes classification is carried out: 1. 0 grade: without pathological changes by following provisions；2. I level: pathological changes accounts for 1～25%；
3. II level: pathological changes accounts for 26～50%；4. III level: pathological changes accounts for 51～75%；5. IV level: pathological changes accounts for
76～100%.Scoring system: 1. 0 grade: count 0 point；2. I level: count 1 point；3. II level: meter 2
Point；4. III level: count 3 points；5. IV level: count 4 points.
1, the present invention impact on AS rabbit model blood fat
Result of the test is shown in Table 1, and result shows, compared with blank group, and TC, TG, LDL of model group
Significantly raised (P ＜ 0.01), HDL substantially reduce (P ＜ 0.01), show modeling success.With model group phase
Ratio, the present invention can significantly reduce TC, TG, LDL level (P ＜ 0.01) in AS model Sanguis Leporis seu oryctolagi；Raise
HDL level (P ＜ 0.01) in AS model Sanguis Leporis seu oryctolagi, effect is better than cannabidiol.
Table 1 present invention on the impact of AS rabbit model blood fat (N=10)
Note: compare with model group: * P ＜ 0.05, * * P ＜ 0.01.
2, the present invention is on AS rabbit model NO, the impact of ET-1
Result of the test is shown in Table 2, and result shows, compared with model group, the present invention can significantly reduce AS mould
ET-1 level in type Sanguis Leporis seu oryctolagi, improves NO level, and is respectively provided with significant (P ＜ 0.01), effect
It is better than cannabidiol.
Table 2 present invention on AS rabbit model NO, ET-1 impact (N=10)
Note: compare with model group: * P ＜ 0.05, * * P ＜ 0.01.
3, the present invention impact on AS rabbit model artery plaque
Result of the test is shown in Table 3, and result shows, compared with model group, the present invention can significantly reduce AS mould
Type rabbit plaque area (P ＜ 0.01), effect is better than cannabidiol.
Table 3 present invention on the impact of AS rabbit model artery plaque (N=10)
| Group | Dosage (mg/Kg) | Speckle is scored |
| Normal control sample | - | - |
| Model comparison sample | - | 3.7±.62 |
| Cannabidiol group | 20 | 2.4±0.67* |
| A group of the present invention | 20 | 1.3±0.73** |
| B group of the present invention | 20 | 1.2±0.91** |
| C group of the present invention | 20 | 1.5±0.89** |
Note: compare with model group: * P ＜ 0.05, * * P ＜ 0.01.
In sum, the present invention can substantially reduce blood fat, improve serum NO levels, reduce ET-1 contain
Amount, and suppress plaque progression, above-mentioned effect is that it treats atherosclerotic pharmacological basis.
Claims (6)
1. treat atherosclerotic medicine for one kind, it is characterised in that by the raw material of following weight parts
Mixing is made: industrial hemp Fructus Cannabis extract 0.3 part～99.7 parts, industrial hemp Urtica cannabina L. element 99.7
Part～0.3 part.
The atherosclerotic medicine for the treatment of the most according to claim 1, it is characterised in that: institute
The raw material composition stating medicine is preferably industrial hemp Fructus Cannabis extract 40 parts and industrial hemp Urtica cannabina L. element 60
Part.
The atherosclerotic medicine for the treatment of the most according to claim 1, it is characterised in that: institute
The industrial hemp Fructus Cannabis extract stated is prepared by the following method and forms:
(1) ripe industrial hemp Fructus Cannabis is taken, drying, remove impurity, standby after pulverizing；
(2) under the conditions of 20～85 DEG C, extracting pulverizing Fructus Cannabis material with ethanol, ethanol is dense
Degree is 95%～100% (V/V), and solid-liquid ratio is 1: 5～1: 20；
(3) leach lixiviating solution, after concentrating under reduced pressure, be industrial hemp Fructus Cannabis extract.
The atherosclerotic medicine for the treatment of the most according to claim 1, it is characterised in that: institute
The industrial hemp Urtica cannabina L. element stated is prepared by the following method and forms:
(1) flower of industrial hemp, leaf, fiber crops bran or the mixture of three, drying, remove impurity, powder are taken
It is broken to 10～60 mesh；
(2) supercritical carbon dioxide extraction: the above-mentioned industrial hemp raw material crushed is put into supercritical
In carbon dioxide extraction apparatus, control extraction temperature 40～50 DEG C, extraction time 30～90min, extraction
Pressure power 25～35Mpa, carbon dioxide flow 40kg/h, extract is collected in separating still outlet；
(3) the extract ethanol elution of 95%～100% (V/V) of 0.2～10 times of volume,
Washing steps is 1～3 time；
(4) eluent is collected, concentrating under reduced pressure, vacuum drying, i.e. obtain industrial hemp Urtica cannabina L. element after pulverizing.
The atherosclerotic medicine for the treatment of the most according to claim 4, it is characterised in that: institute
The flower of the industrial hemp stated, leaf, the optimum ratio of fiber crops bran three's mixture are 1: 3: 2.
6. according to the atherosclerotic medicine for the treatment of described in claim 1 or 2 or 3 or 4 or 5,
It is characterized in that: the kind of described industrial hemp is preferably " cloud fiber crops No. 1 ".
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610415112.2A CN105963357A (en) | 2016-06-14 | 2016-06-14 | Drug for treating atherosclerosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610415112.2A CN105963357A (en) | 2016-06-14 | 2016-06-14 | Drug for treating atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105963357A true CN105963357A (en) | 2016-09-28 |
Family
ID=57011200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610415112.2A Pending CN105963357A (en) | 2016-06-14 | 2016-06-14 | Drug for treating atherosclerosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105963357A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019232783A1 (en) * | 2018-06-08 | 2019-12-12 | 云南汉素生物科技有限公司 | Cannabidiol composition and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105505565A (en) * | 2015-12-28 | 2016-04-20 | 贵州航天乌江机电设备有限责任公司 | Method for extracting industrial hemp oil rich in cannabidiol |
-
2016
- 2016-06-14 CN CN201610415112.2A patent/CN105963357A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105505565A (en) * | 2015-12-28 | 2016-04-20 | 贵州航天乌江机电设备有限责任公司 | Method for extracting industrial hemp oil rich in cannabidiol |
Non-Patent Citations (1)
| Title |
|---|
| 赵翾等: "响应面法优化火麻仁黄酮提取工艺", 《食品科学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019232783A1 (en) * | 2018-06-08 | 2019-12-12 | 云南汉素生物科技有限公司 | Cannabidiol composition and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103053748B (en) | Kudzu vine root fat-reducing sugar-reducing health-care tea and preparation method thereof | |
| CN104322617B (en) | Biscuit of a kind of auxiliary hyperglycemic and preparation method thereof | |
| CN103734428B (en) | A kind of glossy privet fruit health-care tea improving immunity and preparation method thereof | |
| CN105943615A (en) | Application of whole hemp extract in preparation of pancreatic cancer treating drug | |
| CN105943618A (en) | Drug for treating depression | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN104305205A (en) | Cuscuta chinensis oral liquid for improving immunity and preparation method of cuscuta chinensis oral liquid | |
| CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| CN105935374A (en) | Application of Quanmasu in preparation of drugs for treatment of diabetes | |
| CN105943613A (en) | Application of whole hemp extract in preparation of drug for preventing and controlling cardiovascular and cerebrovascular diseases | |
| CN106074707A (en) | The application in pancreatitic medicine is treated in preparation of the general anesthesia element | |
| CN105998194A (en) | Antithrombotic medicine | |
| CN105943617A (en) | Application of whole hemp extract in preparation of anti-hepatitis drugs | |
| CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
| CN104223297A (en) | Aging-delaying health schisandra chinensis oral solution and preparation method thereof | |
| CN105963359A (en) | Application of all-cannabinoid in preparation of drugs for treating depression | |
| CN105963355A (en) | Medicine for preventing and treating senile dementia | |
| CN105943619A (en) | Application of whole hemp extract in preparation of drug for preventing and treating Alzheimer's disease | |
| CN102823700A (en) | Preparation method of compound poria cocos and black garlic filled chocolate | |
| CN105998192A (en) | Application of industrial cannabinoid in preparing drugs for treating gouty arthritis | |
| CN105963357A (en) | Drug for treating atherosclerosis | |
| CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN105998191A (en) | Application of general anesthetic to preparation of drugs for treating gout | |
| CN106074710A (en) | A kind of medicine treating epilepsy | |
| CN105920104A (en) | Age-defying drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Chenfeng Inventor after: Hu Chengyue Inventor before: Chen Tianrui Inventor before: Hu Chengyue |
|
| CB03 | Change of inventor or designer information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160928 |
|
| RJ01 | Rejection of invention patent application after publication |